The Point Prevalence Program (PPP) is a collaborative project between Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG) and the Critical Care Division of The George Institute. Aim As a coordinated and validated project , the Point Prevalence Program provides  infrastructure to conduct several multi-centre observational studies simultaneously on specified study days each year. The impetus for the PPP is to improve the efficiency of the collection of observational data that helps design clinical trial protocols for future ANZICS CTG studies. A further use of the PPP is that it can help with generating data to understand how research findings are translated into clinical practice. Significance The program facilitates collaborations amongst members of the CTG with an average of 44 ICUs participating each study day from a range of tertiary, metropolitan, regional-rural and private hospitals with an average recruitment per study day of more than 550 participants.

Hyperglycaemia is a common finding in patients who are acutely ill even in the absence of a prior diagnosis of diabetes mellitus. In acutely ill patients, hyperglycaemia is associated with a worse outcome. As hyperglycaemia is consistently associated with increased morbidity and mortality, critical care researchers have conducted a number of trials to investigate whether tighter control of blood glucose in critically ill patients is beneficial. To date there have been over 30 randomised controlled trials of tight glucose control in critical care settings. However, many studies have reported non-significant results; in part this is because many of the trials were small and when considered alone had insufficient statistical power to examine the effects of tight glucose control on mortality. Aims The aim of this collaborative research project is to combine the individual patient data from all randomized controlled trials of tight glucose control in critically ill adults around the world to conduct